TY - JOUR
T1 - Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration
AU - Abernethy, D. R.
AU - Wainer, I. W.
AU - Longstreth, J. A.
AU - Andrawis, N. S.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1993
Y1 - 1993
N2 - Stereoselective verapamil disposition and dynamics were evaluated after racemic verapamil administration of single i.v. doses, simulated steady- state intravenous infusions, chronic (1 week) administration of oral immediate-release tablets (120 mg three times daily) and chronic (1 week) administration of oral sustained-release tablets (240 mg once daily) to 15 young (mean ± S.E.M. age 22 ± 1 year) and 15 older (69 ± 1 year) healthy male volunteers. After single i.v. doses S-verapamil clearance (young, 102 ± 6 vs. older, 77 ± 6 l/hr; P < .01) and R-verapamil clearance (young, 61 ± 3 vs. older, 45 ± 3 l/hr; P < .01) were similarly decreased. Electrocardiographic P-R prolongation using S-verapamil concentrations and an E(max) model (young E(max), 69 ± 8 vs. older, 42 ± 6 msec; P < .05: young EC50, 15 ± 1 vs. older, 23 ± 3 ng/ml; P < .05) was greater in the young. Simulated steady-state i.v. S-verapamil clearance (young, 76 ± 3 vs. older, 49 ± 2 l/hr; P < .01) and R-verapamil clearance (young, 47 ± 2 vs. older, 28 ± 1 l/hr; P < .01) were similarly less in older subjects and this was unrelated to infusion rate. Qualitatively similar findings were observed during chronic oral (immediate release) treatment and chronic oral (sustained release) treatment. Plasma protein binding of S-verapamil was less in both groups (young, 8.5 ± 0.4 and older, 8.0 ± 0.5% unbound) than that of R- verapamil (young, 5.4 ± 0.2 and older, 5.1 ± 0.3% unbound) and not different between groups. Clearance of both pharmacologically active S- verapamil and R-verapamil is less in older subjects after nonsteady-state and steady-state i.v. and oral racemic verapamil administration. Verapamil- induced cardiac A-V nodal conduction delay is greater in young subjects and this is not due to age-related stereoselective verapamil disposition.
AB - Stereoselective verapamil disposition and dynamics were evaluated after racemic verapamil administration of single i.v. doses, simulated steady- state intravenous infusions, chronic (1 week) administration of oral immediate-release tablets (120 mg three times daily) and chronic (1 week) administration of oral sustained-release tablets (240 mg once daily) to 15 young (mean ± S.E.M. age 22 ± 1 year) and 15 older (69 ± 1 year) healthy male volunteers. After single i.v. doses S-verapamil clearance (young, 102 ± 6 vs. older, 77 ± 6 l/hr; P < .01) and R-verapamil clearance (young, 61 ± 3 vs. older, 45 ± 3 l/hr; P < .01) were similarly decreased. Electrocardiographic P-R prolongation using S-verapamil concentrations and an E(max) model (young E(max), 69 ± 8 vs. older, 42 ± 6 msec; P < .05: young EC50, 15 ± 1 vs. older, 23 ± 3 ng/ml; P < .05) was greater in the young. Simulated steady-state i.v. S-verapamil clearance (young, 76 ± 3 vs. older, 49 ± 2 l/hr; P < .01) and R-verapamil clearance (young, 47 ± 2 vs. older, 28 ± 1 l/hr; P < .01) were similarly less in older subjects and this was unrelated to infusion rate. Qualitatively similar findings were observed during chronic oral (immediate release) treatment and chronic oral (sustained release) treatment. Plasma protein binding of S-verapamil was less in both groups (young, 8.5 ± 0.4 and older, 8.0 ± 0.5% unbound) than that of R- verapamil (young, 5.4 ± 0.2 and older, 5.1 ± 0.3% unbound) and not different between groups. Clearance of both pharmacologically active S- verapamil and R-verapamil is less in older subjects after nonsteady-state and steady-state i.v. and oral racemic verapamil administration. Verapamil- induced cardiac A-V nodal conduction delay is greater in young subjects and this is not due to age-related stereoselective verapamil disposition.
UR - http://www.scopus.com/inward/record.url?scp=0027440330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027440330&partnerID=8YFLogxK
M3 - Article
C2 - 8355215
AN - SCOPUS:0027440330
SN - 0022-3565
VL - 266
SP - 904
EP - 911
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 2
ER -